Inovio to update HVTN 080 Phase I clinical study for HIV at HVTN Conference

Inovio Pharmaceuticals, Inc. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX^TM-B HIV DNA vaccine in a preventive setting. Dr. Kalams, principal investigator of this clinical study, is Immunology Director of the Vanderbilt Center for AIDS Research at Vanderbilt University Medical Center, and Associate Professor of Medicine and Associate Professor of Microbiology and Immunology at Vanderbilt University. The multi-center study is being conducted by Inovio's clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites and is sponsored by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH).

Presentation details:

PENNVAX-B is being tested under a protocol designated HVTN-080. Inovio previously announced the completion of enrollment of 48 healthy volunteers.

Inovio previously reported data from non-human primates demonstrating up to a 100-fold enhancement in immune responses resulting from the vaccine when delivered via in vivo electroporation compared to syringe injection without electroporation. The HVTN-080 study is assessing safety and levels of immune responses in humans.

Source : Inovio Pharmaceuticals, Inc.